NEW ORLEANS – Two tropomyosin receptor kinase (TRK) inhibitors presented at the annual meeting of the American Association for Cancer Research (AACR) had a high success rate in shrinking tumors with TRK fusions – and doing so for longer periods than inhibitors that target activating mutations are typically able to do.